Resources

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 1071

A New Era for HIV

The global HIV response has changed fundamentally. Now, the question is: what comes next? Home to the world’s largest HIV programme, South Africa is at a critical turning point. As global funding models shift and traditional approaches to HIV...

December 3, 2026


Advancing Access to LEN for PrEP

AVAC is pleased to share, Advancing Access to LEN for PrEP, highlighting the approaches that led to strong, sustainable, community-centered LEN introductions in Kenya, Malawi and Uganda. It documents the lessons learned and shares resources that can help other countries determine how to effectively prepare for and deliver LEN and future PrEP options.

Prevention Option:

November 2026


Advancing Access to LEN for PrEP in Kenya, Malawi and Uganda: Communications Toolkit

These communication materials were created during the Advancing Access to LEN for PrEP projects in Kenya, Malawi and Uganda. Partners worked with government and communities to develop tailored materials to raise awareness of LEN for PrEP, situating it among other available prevention options as a way of facilitating informed choice. Across the three countries, 36 demand-generation materials were developed with community input.

Prevention Option:

November 2026


Going Faster with LEN Generics

The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.

Prevention Option:

November 2026


Understanding Anal Pleasure and Health: There’s Always More to Know

The public health response to the HIV epidemic can narrow our attention to the potential harms of anal sex. Forty-five years into the epidemic, people are still seeking accurate, reliable information about anal play that goes beyond HIV and STI...

December 9, 2026


Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.

Prevention Option:

November 2026


Source of Lenacapavir for PrEP Supply in Africa

Lenacapavir for PrEP has now reached seventeen countries in Africa. This map offers more detail on the LEN rollout.

Prevention Option:

November 2026


Advancing Access to LEN for PrEP in Kenya, Malawi, and Uganda

Reflections and lessons learned from partners and Ministries of Health on projects to support locally tailored, sustainable, choice-centered rollout of injectable Lenacapavir (LEN) Since its launch in December 2025, LEN for PrEP has been...

November 18, 2026


New Congress, who dis? Understanding how power has shifted after the election

How will power shift with the new Congress? The Positive Women’s Network-USA hosts a webinar that digs into how political power will shift after the election and what the results mean for people living with HIV in the US and abroad. Panelists:

November 16, 2026


Preparing for LEN

In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.

Prevention Option:

November 2026


showing 1-10 of 1071